These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings. Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170 [TBL] [Abstract][Full Text] [Related]
10. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan. Liu RC Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction. Sandhu AT; Kohsaka S; Turakhia MP; Lewis EF; Heidenreich PA JAMA Cardiol; 2022 Feb; 7(2):130-139. PubMed ID: 34757380 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Sacubitril-Valsartan on Survival and Cardiac Remodeling in Hypotensive Heart Failure With Reduced Ejection Fraction: A Multicenter Study. Hsu CY; Chung FP; Chao CJ; Chen YJ; Wu CK; Wu YW; Huang JL; Chu PH; Jia-Yin Hou C; Chang HY; Hung CL Mayo Clin Proc; 2024 Jun; 99(6):940-952. PubMed ID: 38530689 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update. Hellenkamp K; Nolte K; von Haehling S Expert Opin Pharmacother; 2022 Apr; 23(6):673-680. PubMed ID: 35260016 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961 [TBL] [Abstract][Full Text] [Related]
15. Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review. King JB; Bress AP; Reese AD; Munger MA Pharmacotherapy; 2015 Sep; 35(9):823-37. PubMed ID: 26406774 [TBL] [Abstract][Full Text] [Related]
16. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR). Ekici B; Yaman M; Küçük M; Dereli S; Yenerçağ M; Yiğit Z; Baş MM; Karavelioğlu Y; Çakmak HA; Kıvrak T; Özkan H; Altın C; Şabanoğlu C; Demirkan B; Ataş AE; Kılıçaslan F; Altay H; Tengiz İ; Fahri Erkan A; Kılıçaslan B; Olgun FE; Durakoğlugil ME; Alhan A; Zoghi M Turk Kardiyol Dern Ars; 2021 Jul; 49(5):357-367. PubMed ID: 34308869 [TBL] [Abstract][Full Text] [Related]
17. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956 [TBL] [Abstract][Full Text] [Related]
18. Severe Hypotension With Concomitant Sodium-Glucose Co-Transporter-2 Inhibitor and Angiotensin Receptor-Neprilysin Inhibitor Therapy in a Patient With Heart Failure Reduced Ejection Fraction: A Case Report. Schumacher C J Pharm Pract; 2024 Apr; 37(2):495-499. PubMed ID: 36441976 [No Abstract] [Full Text] [Related]
19. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry). Jiménez-Blanco Bravo M; Valle A; Gayán Ordás J; Del Prado Díaz S; Cordero Pereda D; Morillas Climent H; Bascompte Claret R; Seller Moya J; Zamorano Gómez JL; Alonso Salinas GL J Cardiovasc Pharmacol; 2021 Nov; 78(5):e662-e668. PubMed ID: 34321396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]